Roivant Sciences Ltd.
ROIV
Classement en actions
#978
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Prix de l'action
$33.73
Dernière synchronisation: 2026-07-31
Capitalisation boursière
$24.37B
Changement (1 jour)
-2.28%
Changement (1 an)
90.15%
Pays
GB
Échange Roivant Sciences Ltd. (ROIV)
Catégorie
Healthcare
Ratio P/S pour Roivant Sciences Ltd. (ROIV)
Ratio P/S au October 2026 TTM : 3.22K
Selon les derniers rapports financiers et le cours de l'action de Roivant Sciences Ltd., le ratio cours/ventes actuel (TTM) est 3.22K. À la fin de 2024, le ratio P/S était de 65.46.
Historique du ratio P/S pour Roivant Sciences Ltd. de 2020 à 2026
Ratio P/S à la fin de chaque année
| Année | Ratio P/S | Changez |
|---|---|---|
| 2026 (TTM) | 3.22K | 1,179.79% |
| 2025 | 251.93 | 284.85% |
| 2024 | 65.46 | -23.74% |
| 2023 | 85.84 | 43.44% |
| 2022 | 59.84 | -78.74% |
| 2021 | 281.46 | 167.51% |
| 2020 | 105.21 | 0.00% |
Ratio P/S pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/S | Différence de Ratio P/S | Pays |
|---|---|---|---|
| 10.02 | -99.69% |
US
|
|
| 40.55 | -98.74% |
US
|
|
| 3.96 | -99.88% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -99.69% |
NL
|
